Talcum Powder Lawsuit

The Science Linking Talc to Cancer

The epidemiological evidence linking perineal talc use to ovarian cancer spans more than four decades. The first major study, published by Daniel Cramer and colleagues in The Lancet in 1982, found that women who used talcum powder in the perineal area had approximately twice the risk of developing ovarian cancer compared to non-users (OR = 1.92). Subsequent studies, including analyses from the Harvard Nurses’ Health Study and the Women’s Health Initiative, have confirmed a consistent positive association, typically finding a 20% to 40% increased risk with regular perineal talc use.

The biological mechanism by which talc reaches the ovaries is well established. Talc particles applied to the perineal area migrate through the vaginal canal, uterus, and fallopian tubes to the ovarian surface. Talc particles have been found embedded in ovarian tissue and ovarian tumors removed during surgery. Once lodged in ovarian tissue, talc triggers a chronic inflammatory response that promotes cellular proliferation and, over time, malignant transformation. This mechanism — chronic inflammation leading to cancer — is well recognized in oncology and parallels the carcinogenic process of asbestos in mesothelioma.

The IARC’s July 2024 upgrade of talc to Group 2A ("probably carcinogenic to humans") in Monograph Volume 136 was based on three pillars of evidence: limited but consistent evidence in humans from epidemiological studies, sufficient evidence of carcinogenicity in animal studies, and strong mechanistic evidence including chronic inflammation and altered cell proliferation. The IARC working group specifically noted the consistency of epidemiological findings across multiple study designs and populations.

The asbestos contamination pathway presents a separate but complementary mechanism of carcinogenesis. Asbestos fibers — including tremolite, anthophyllite, and chrysotile — have been detected in J&J talc products through independent testing. Asbestos is a Group 1 carcinogen (definite human carcinogen) with no safe level of exposure. Inhalation or ingestion of asbestos fibers causes mesothelioma, lung cancer, and peritoneal cancer. The presence of asbestos in a consumer product marketed for daily intimate use represents a profound failure of product safety.

J&J’s Decades of Concealment

The evidentiary record in the talcum powder litigation reveals a pattern of corporate concealment spanning decades. Internal J&J memos from the 1970s — obtained through discovery and later made public through litigation — show that company scientists and executives were aware of asbestos contamination in their talc products. Rather than reformulating, warning consumers, or withdrawing the product, J&J chose to suppress this information and continue marketing Baby Powder as safe and pure.

The December 2018 Reuters investigative report, "J&J Knew for Decades That Asbestos Lurked in Its Baby Powder," documented how J&J had evidence of asbestos in Baby Powder stretching back to the early 1970s, fought to keep damaging documents sealed in litigation, influenced scientific research to minimize concerns about talc safety, and continued aggressive marketing — including campaigns specifically targeting African-American women — despite accumulating evidence of cancer risk.

J&J’s marketing to African-American women is a particularly troubling element of the litigation. Court documents and internal marketing materials reveal that J&J specifically targeted Black women with talcum powder advertising, promoting heavy use of Baby Powder for personal hygiene in communities that were already disproportionately affected by ovarian cancer. This targeted marketing, combined with the company’s knowledge of cancer risk, has been characterized by plaintiffs’ attorneys and juries as evidence of willful and reckless disregard for consumer safety.

The Bankruptcy Strategy and Its Failure

In October 2021, J&J executed what is known as the "Texas two-step" bankruptcy strategy. The company created a subsidiary called LTL Management LLC, transferred all of its talc liabilities to this shell entity through a Texas divisional merger, and then had LTL file for Chapter 11 bankruptcy in a bankruptcy-friendly New Jersey court. The strategy was designed to cap J&J’s talc liability at $8.9 billion through a bankruptcy trust, far less than the potential exposure from tens of thousands of individual lawsuits.

The Third Circuit Court of Appeals rejected LTL’s bankruptcy petition twice — first in January 2023 and again in 2025 — finding that the filing was not made in good faith because LTL was not in financial distress. The court noted that J&J, a company with approximately $400 billion in market capitalization, had created a subsidiary for the sole purpose of shielding itself from legitimate tort claims. The rejection of the Texas two-step strategy was widely seen as a landmark ruling that prevents large corporations from using bankruptcy as a tort shield.

The failure of the bankruptcy strategy means that the tens of thousands of pending talcum powder lawsuits will proceed through the traditional litigation process, including the MDL 2738 bellwether trials in the District of New Jersey and individual state court proceedings. For plaintiffs, this outcome preserves the possibility of significant individual verdicts and settlements uncapped by a bankruptcy trust.